James Strauss

Also affiliated with Mirna Therapeutics (United States), Diapin Therapeutics (United States)

Biochemistry, Genetics and Molecular BiologyImmunology and MicrobiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Manufacturing‐dependent change in biological activity of the TLR4 agonist GSK1795091 and implications for lipid A analog development”.

Manufacturing‐dependent change in biological activity of the TLR4 agonist GSK1795091 and implications for lipid A analog development

Clinical and Translational Science(2022)10.1111/cts.13387

N/A

0.655DataRank · unranked

16 citations

Aaron R. Hansen, Glenn J. Hanna, Elena Garralda, Haeseong Park, James Strauss +11 more

First in human phase 1 study of DT2216, a selective BCL-xL degrader, in patients with relapsed/refractory solid malignancies

Journal of Hematology & Oncology(2025)10.1186/s13045-025-01753-8

N/A

0.436DataRank · unranked

14 citations

Minal Barve, Devalingam Mahalingam, Jay Parekh, Michael R. Kurman, James Strauss +10 more

Interim phase 1 results for SQ3370 in advanced solid tumors.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.3085

N/A

0.241DataRank · unranked

4 citations

Kathleen Batty, Maša Alečković, Vivek A. Bhadri, Nam Q. Bui, Alexander Guminski +10 more